TargetMol

S29434

Product Code:
 
TAR-T7149
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7149-1mg1mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7149-5mg5mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7149-1mL1 mL * 10 mM (in DMSO)£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7149-10mg10mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7149-25mg25mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7149-50mg50mg£544.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
S29434 (NMDPEF) is a potent, competitiveinhibitor of quinone reductase 2 (QR2;IC50:5-16nM).
CAS:
874484-20-5
Formula:
C21H18N4O3
Molecular Weight:
374.4
Pathway:
Metabolism; Autophagy
Purity:
0.9992
SMILES:
COc1ccc2n3Cc4cccnc4-c3c(CCNC(=O)c3ccco3)c2n1
Target:
NADPH; Autophagy

References

Laure-Estelle C , Nambinina R , Serena S , et al. Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives[J]. Molecules, 2017, 22(2):210-. Boutin JA, Bouillaud F, Janda E,et al.S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization[J].Mol Pharmacol. 2019 Mar;95(3):269-285.